BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 23, 2012
 |  BioCentury  |  Product Development

Debio's dual deal

Debiopharm sees best-in-class potential in cancer deal with China's Ascepion

Debiopharm Group has been stocking up its early stage cancer pipeline with assets it believes have best-in-class potential, the latest being a preclinical dual tyrosine kinase inhibitor from Ascepion Pharmaceuticals Inc. The deal is the first for Ascepion, which set up shop in 2007 after its management team returned to China following stints in academia and industry in the West.

Debiopharm in-licenses compounds in or near the clinic and then seeks to out-license the molecules to pharma prior to commercialization.

Since the start of 2011, Debiopharm has acquired rights to one Phase I agent and three preclinical programs in the oncology space.

The most advanced, Debio 1143, is an IAP (inhibitor of apoptosis) antagonist in Phase I testing for acute myelogenous leukemia (AML) and solid tumors. Debiopharm licensed it from Ascenta Therapeutics Inc. last September.

Earlier last year, Debiopharm licensed Debio 1142, an undisclosed compound for solid...

Read the full 743 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >